Articles related to GUIDELINES/RECOMMENDATIONS

In the latest examination of DSM-5-TR, it’s revealed that nearly 60% of its panel members received payments from the pharmaceutical industry, highlighting the pervasive nature of financial conflicts in shaping psychiatric standards.

In an insightful study on major depressive disorder, it was found that an increase in guideline concordance, as measured by the GCA-8 score, was associated with a notable improvement in patient-reported depression symptoms, emphasizing the need for rigorous adherence to established treatment protocols.

Recent evidence suggests that shorter preoperative fasting, as recommended by major anesthesiology societies, can enhance patient comfort without increasing surgical risks.

The FDA’s guidance on psychedelic medicine is a landmark in mental health treatment. With the potential to treat PTSD, addiction, and treatment-resistant depression, psychedelics could heighten the field. However, the guidance also highlights the need for rigorous study of these substances, particularly regarding their subjective effects and the role of psychological support.

The commentary presents a compelling analysis of the paradoxical views on long-term benzodiazepine treatment, highlighting the need for evidence-based practice guidelines. It underscores the importance of considering both the challenges of withdrawal and the potential efficacy of long-term use in well-characterized DSM anxiety disorders.

As pharmacists, it’s crucial to note that, although these changes in FDA guidelines may not directly impact your practice, they signify a shift in how biosimilars will be identified moving forward. This could potentially influence how you advise patients about these products.